Nektar Therapeutics disclosed additional hair-regrowth data from a 16-week extension of its Phase IIb REZOLVE-AA study of rezpegaldesleukin (rezpeg), highlighting deeper responses among late responders in severe alopecia areata. The company said rezpeg drove additional regrowth during the extension period.